What's Happening?
The Gates Institute, located at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex Grant by ScaleReady. This grant aims to develop a modular CAR-T cell manufacturing platform. The initiative is supported by Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady. The grant will facilitate a structured Design of Experiments to optimize key manufacturing steps, enhancing the efficiency and adaptability of cell and gene therapy programs. The Gates Institute will also gain early access to CellReady's G-CAR-TTM, a standardized CAR-T drug product manufacturing operation. This development is part of ScaleReady's broader effort to advance cell and gene-modified cell therapy manufacturing.
AD
Why It's Important?
The grant awarded to the Gates Institute is significant for the field of cell and gene therapy, particularly in the manufacturing of CAR-T cells, which are crucial in treating cancers and rare diseases. The modular platform aims to optimize space, capital, and personnel while maintaining cell health and quality. This advancement could lead to more efficient and cost-effective production of cell therapies, potentially accelerating the availability of life-saving treatments. The collaboration with industry leaders like Wilson Wolf and Bio-Techne underscores the importance of integrating academic research with clinical applications to drive innovation in healthcare.
What's Next?
The Gates Institute will proceed with the Design of Experiments to refine the CAR-T cell manufacturing process. The data collected will help define process conditions and product attributes, offering a range of manufacturing options for novel therapies. Additionally, ScaleReady has introduced a free program, LEAN Cell & GeneTM, to promote efficient CGT manufacturing practices. This initiative invites CGT entities to learn how to eliminate waste and stabilize operations, further supporting the development of high-quality cell and gene therapies.
